Is metformin safe for treating gestational diabetes in pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Metformin Should NOT Be Used as First-Line Treatment for Gestational Diabetes

Insulin is the preferred first-line medication for treating gestational diabetes mellitus when lifestyle modifications fail to achieve glycemic control. 1, 2 Metformin should not be used as a first-line agent because it crosses the placenta to the fetus, and there are concerning long-term safety data regarding offspring outcomes. 1, 2

Why Insulin Remains First-Line

The most recent and authoritative guidelines (2023-2025 ADA Standards of Care) consistently state that insulin is the preferred medication because:

  • It does not cross the placenta to a measurable extent
  • It has decades of proven safety data
  • It effectively improves perinatal outcomes when combined with lifestyle modification 2

The Problem with Metformin: Placental Transfer and Offspring Concerns

Metformin readily crosses the placenta, resulting in umbilical cord blood levels as high or higher than maternal levels. 2 This is not theoretical—it's measured and documented.

Long-Term Offspring Data Raises Red Flags

The most concerning evidence comes from follow-up studies:

  • MiG TOFU study (Auckland cohort): 9-year-old children exposed to metformin in utero were heavier with higher waist-to-height ratios and waist circumferences compared to insulin-exposed children 2, 3
  • PCOS studies: 4-year-old offspring showed higher BMI and increased obesity; 5-10 year follow-up confirmed higher BMI, weight-to-height ratios, and waist circumferences 2, 3
  • Meta-analysis findings: Metformin exposure resulted in smaller neonates with acceleration of postnatal growth, leading to higher BMI in childhood 2, 3

When Metformin May Be Considered (Second-Line Only)

Metformin can be used as an alternative in specific circumstances 2:

  • When patients cannot use insulin safely or effectively due to cost, language barriers, comprehension issues, or cultural factors
  • Only after discussing known risks and the need for more long-term safety data
  • Must be outside the first trimester 4

Absolute Contraindications to Metformin in Pregnancy

Do not use metformin if the patient has: 2

  • Hypertension or preeclampsia
  • Risk factors for intrauterine growth restriction
  • Placental insufficiency concerns

The rationale: potential for growth restriction or acidosis in these settings.

Short-Term Benefits Don't Override Long-Term Concerns

While metformin does show some maternal benefits:

  • Lower risk of neonatal hypoglycemia 2, 5
  • Less maternal weight gain 2, 5
  • Reduced macrosomia rates 5, 6

These short-term benefits must be weighed against the documented long-term metabolic effects on offspring. The 2024-2025 guidelines explicitly state that data on long-term safety for offspring is "of some concern." 2

The Guideline Evolution Shows Increasing Caution

Note the progression: The 2013 Endocrine Society guideline 4 was more permissive about metformin use, but the most recent 2023-2025 ADA guidelines 1, 2 have become more restrictive as long-term offspring data has emerged. This represents appropriate evidence-based caution.

Clinical Algorithm

  1. Diagnose GDM → Start lifestyle modifications (medical nutrition therapy + exercise)
  2. If glycemic targets not met after 1-2 weeks → Start insulin
  3. If insulin is refused/cannot be used safely → Consider metformin as second-line ONLY IF:
    • Not in first trimester
    • No hypertension/preeclampsia
    • No risk of intrauterine growth restriction
    • After thorough discussion of offspring risks
  4. Monitor closely: 25-46% of patients on metformin will require supplemental insulin anyway 7

Common Pitfall to Avoid

Do not continue metformin started for PCOS/ovulation induction into pregnancy. Metformin used for polycystic ovary syndrome should be discontinued by the end of the first trimester. 1 There is no evidence-based need to continue it, as it does not prevent GDM in these patients. 2, 7

The FDA drug label 8 acknowledges limited data in pregnancy and states studies "cannot definitely establish the absence of any metformin-associated risk." This regulatory uncertainty, combined with documented offspring metabolic effects, supports the guideline recommendation for insulin-first approach.

References

Guideline

diabetes and pregnancy: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2013

Research

Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.